Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib for Post-Hematopoietic Stem Cell Transplant Immune-Mediated Cytopenias
NCT05502783Phase 2Terminated
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fostamatinib in autoimmune hemolytic anemia (AIHA), immune-mediated thrombocytopenia (ITP), Evans syndrome, sponsored by National Heart, Lung, and Blood Institute. Started Mar 2023; status: terminated.
02
Drugs
fostamatinib
03
Conditions
autoimmune hemolytic anemia (AIHA)immune-mediated thrombocytopenia (ITP)Evans syndrome
Beyond the preview
Go deeper on NCT05502783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05502783.